| According to TechCrunch, many bioinformatics start-up business incubators MBC Biolabs, headquartered in the Dogpatch community in San Francisco, USA, are working with small start-ups Prellis Biologics to help them develop portable 3D printed human organs. A big step.  Founded in 2016, Prellis Biologics co-founders include research scientists Melanie Matheu and Noelle Mullin. The company has its own future (and $3 million in investment). Betting on new technologies for the manufacture of capillaries. Capillaries are blood vessels that are only 1 cell thick and act as channels for transport of oxygen and nutrients to help nurture various organs in the body. Matthew explained that if there is no functioning capillary structure, it is impossible to make an organ. She said that in the process of printing the heart, liver, kidneys and lungs, they are one of the most important puzzles. Assistant professor of bioengineering at Rice University, Jordan Miller, an expert in 3D printing implantable biomaterials, said in a statement: 'The capillary system is the basic building unit that supports advanced multicellular life. It is therefore an important goal of bottom-up human organ engineering and regenerative medicine. Now, research published by Prellis Biologics shows that it can produce 3D printed organs at a specific size and speed, and it will be put on the market within the next five years. The company uses holographic printing technology to generate light-induced chemical reactions in 5 milliseconds. The three-dimensional layer. Prellis Biologics company said that this function is essential for the construction of kidneys or lungs and other organ tissues. Prellis Biologics achieve this by combining photoinitiator with traditional bio-ink. Traditional bio-ink can make cell material. The reaction occurs under infrared irradiation to catalyze the polymerization of bio-ink. Prellis Biologics is not the inventor of holographic printing technology. Many researchers are looking to apply this new method to 3D printing programs in multiple industries, but the company is applying it to bio-manufacturing in a very promising way. Medium. In this process, speed is critical because it means that cells do not die, and printed organ tissue can still develop on its own. The ability to print inside the structure means that Prellis' technology can generate internal stents. Support and maintain the development of the surrounding organic material. Prellis Biologics is not the first company to develop 3D organ printing technology. Research on this technology has been going on for decades. Companies like BioBots have reduced the cost of printing live tissue. Now that BioBots has changed its name to Allevi, its original intention and business strategy have been changed. Now it is more focused on developing software to make its bioprinter easier to use. Allevi helps to reduce the cost of bioprinting equipment and its price is less than 10,000. Dollars. But Prellis Biologics believes that the limitations of extrusion printing mean that the technical resolution is too low, the creation of capillary speed is too slow, and it is even more difficult to keep cells alive. Prellis Biologics’ organ needs to be maintained in a bioreactor before being transplanted into an animal. However, the difference is that the company’s goal is to make a complete organ, not a sample tissue or a small cell sample. According to Xiu, bioreactors can simulate biomechanical pressures to ensure that organs work properly. Todd Huffman, chief executive of 3Scan, an advanced digital tissue imaging and data analysis company, said: “The vascular system is a complex organ. Key features are indispensable for engineering organizations with therapeutic value. Advances made by Prellis represent an important milestone in human organ engineering. Matthew estimates that the company will take two and a half years and $15 million to pass the portable 3D printing organ through the first animal experiment. She said: 'We will test the kidneys in animals.' Their goal is to print 1/4 The size of the kidney, transplanted it to the mouse. Matthew said: 'We want to be able to transplant the kidneys into the human body.' Earlier this year, researchers at the University of Manchester in the UK first used stem cells to produce functionally normal human kidney tissue. Scientists implanted a small cluster of capillaries in a petri dish to help hemofilter waste into genetically engineered mice. In vivo. After 12 weeks, the capillaries grow out of the kidneys, which constitute the elements of human kidney function. Matthew said that our ultimate goal is to harvest cells from the patient's body through skin grafts, collection of blood, stem cells or bone marrow, and then use these samples to create cell material to grow organs. She stated: 'The exclusivity of organ tissue is what I am The first thing to consider during the design process is something we can solve. While Prellis Biologics spent time perfecting kidney print technology, the company is looking for partners to apply its manufacturing technology to the development of other organs. Matthew said: 'We will work with other groups and our technology will be nurtured. Before the complete kidney enters the market in many other ways. Last year, the company outlined a market-oriented strategy that included the development of a laboratory-raised organization to produce antibodies for therapeutics and drug development. The first group of target human organ tissues used by Prellis Biologics for clinical development is called islet ( The cells of islets of Langerhans), which is the unit of insulin production in the pancreas. Matthew claims that: 'Type 1 diabetics lose insulin-producing islets at very young ages. If we can replace them, we can give diabetics Provides daily life without daily insulin and blood glucose monitoring. Matheu believes that this technology is not only a new method for printing kidneys, but also brings about a fundamental shift in the field of biomaterial production. She said: 'Imagine if you want to make a tumor for detection. In the lab, you It takes 5 hours to print out a tumor. With our system, you only have 3.5 seconds. This is our baseline optics system. The speed will change dramatically in terms of how to build cells and the basic structure. We will spare no effort to authorize it. These technologies. ' At the same time, with the increasing demand for organ donation, new technologies have also provided solutions to the shortage of transplanted organs. Matthew said that 1 in 7 adults in the United States suffers from certain types of kidney disease. She estimates that there are 90 million. People need kidney transplants at some stage of their lives. About 330 people die from organ failure every day. If there is a way to quickly create organs, these deaths can be avoided. Prellis Biologics estimates that the global organ tissue engineering market will reach US$94 billion by 2024, much higher than 2015, thanks to the surge in human tissue and organ replacement programs, as well as the surge in demand for human tissue for drug discovery and toxicology testing. $23 billion. Matthew said: 'We need to act faster to help people.' |
